投资工具 / 美股
Edwards Lifesciences · EW
数据仅供参考,不构成投资建议。
投资工具 / 美股
数据仅供参考,不构成投资建议。
| 季度 | 截止日 | 申报日 | 营收 | 营收同比 g | Δg | 推导方式 |
|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | 2026-11-04 | $1.72B | +10.5% | −3.2pp | 3M |
| 2026Q2 | 2026-06-30 | 2026-08-04 | $1.74B | +13.6% | −3.1pp | 3M |
| 2026Q1 | 2026-03-31 | 2026-05-06 | $1.65B | +16.7% | +3.4pp | 3M |
| 2025Q4 | 2025-12-31 | 2026-11-04 | $1.57B | +13.3% | −1.4pp | FY-9M |
| 2025Q3 | 2025-09-30 | 2026-11-04 | $1.55B | +14.7% | +2.8pp | 3M |
| 2025Q2 | 2025-06-30 | 2026-08-04 | $1.53B | +11.9% | +5.7pp | 3M |
| 2025Q1 | 2025-03-31 | 2026-05-06 | $1.41B | +6.2% | −3.2pp | 3M |
| 2024Q4 | 2024-12-31 | 2025-02-28 | $1.39B | +9.4% | +0.5pp | 3M |
口径:单季同比;Δg = 本季 g − 上季 g;按财季映射日历季度;申报日可见。† 不连续点(上年同季营收 ≤0 或 Δg 幅度超过 50pp)。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 季度 | 截止日 | 毛利 | 销货成本 | 毛利率 | 环比 | 同比 | Δ² |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $1.35B | $369.2M | 78.5% | +102bp | +71bp | +77bp |
| 2026Q2 | 2026-06-30 | $1.35B | $392.4M | 77.5% | −54bp | −6bp | +58bp |
| 季度 | 截止日 | 合同负债 | CL g | RPO | RPO g | 账单额 | 账单额 g | RPO 覆盖 |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 | 无数据 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 |
| 2026Q2 | 2026-06-30 |
| 季度 | 截止日 | OCF TTM | OCF g | CapEx TTM | CapEx g | FCF TTM | CapEx 密度 | SBC/FCF | SBC/Rev |
|---|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $1.72B | +68.9% | $292.8M | +37.7% | $1.42B | 4.4% | 12.1% | 2.6% |
| 2026Q2 | 2026-06-30 | $1.72B |
| 季度 | 截止日 | 存货 | 存货 g | 营收 g | 剪刀差 | DIO | DIO 同比 |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $1.16B | +1.6% | +10.5% | −8.8pp | 286.6 | −15.0 |
| 2026Q2 | 2026-06-30 | $1.13B | −0.9% | +13.6% | −14.5pp | 263.1 |
| 交易日 | 申报日 | 申报人 | 头衔 | 代码 | 股数 | 价格 | 金额 | 10b5-1 |
|---|---|---|---|---|---|---|---|---|
| 2026-11-10 | 2026-11-10 | Lippis Daniel J. | CVP, TAVR | S | 619 | $104.25 | $64.53K | ✓ |
口径:修正广度 =(近 30 日上调 − 下调)/(上调 + 下调),样本 < 3 不出;只展示衍生指标,不展示一致预期原值。 · 数据截至 2026-11-16 · 来源:Yahoo Finance / Nasdaq
未覆盖(期权覆盖为 S&P 500 期权持仓前 100 名每日、其余每周轮换)
暂无警报
口径:本股的警报事件历史(含基线);事件保留 90 天。
| 2026Q1 | 2026-03-31 | $1.29B | $362.6M | 78.0% | −14bp | −65bp | +12bp |
| 2025Q4 | 2025-12-31 | $1.23B | $343M | 78.1% | +37bp | −77bp | +205bp |
| 2025Q3 | 2025-09-30 | $1.21B | $345.2M | 77.8% | +25bp | −282bp | −46bp |
| 2025Q2 | 2025-06-30 | $1.19B | $344.4M | 77.5% | −113bp | −236bp | −258bp |
| 2025Q1 | 2025-03-31 | $1.11B | $301.6M | 78.7% | −26bp | +22bp | +149bp |
| 2024Q4 | 2024-12-31 | $1.09B | $292.2M | 78.9% | −167bp | −127bp | −201bp |
口径:GM = 毛利/营收;毛利缺失时用 营收−销货成本 推导;环比/同比为基点。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 |
| 无数据 |
| 无数据 |
| 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 |
| 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 |
| 无数据 |
| 2026Q1 | 2026-03-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 | 无数据 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 |
| 2025Q4 | 2025-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 | 无数据 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 |
| 2025Q3 | 2025-09-30 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 | 无数据 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 |
| 2025Q2 | 2025-06-30 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 | 无数据 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 |
| 2025Q1 | 2025-03-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 | 无数据 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 |
| 2024Q4 | 2024-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 | 无数据 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 缺口径:ContractWithCustomerLiability 最后申报于 2023-12-31 | 无数据 |
缺口径:合同负债(ContractWithCustomerLiability 最后申报于 2023-12-31)
口径:g = 同比;账单额 = 营收 + Δ合同负债(同口径);RPO 覆盖 = RPO / TTM 营收。跨口径(总额/仅流动)不比较。 合同负债口径: — · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| +116.4% |
| $286.7M |
| +38.5% |
| $1.43B |
| 4.4% |
| 11.7% |
| 2.6% |
| 2026Q1 | 2026-03-31 | $1.36B | +55.1% | $269.1M | +10.7% | $1.09B | 4.3% | 15.0% | 2.6% |
| 2025Q4 | 2025-12-31 | $1.6B | +194.2% | $260.2M | +3.1% | $1.34B | 4.3% | 11.8% | 2.6% |
| 2025Q3 | 2025-09-30 | $1.02B | +26.1% | $212.6M | −26.9% | $804.2M | 3.6% | 18.7% | 2.6% |
| 2025Q2 | 2025-06-30 | $794.9M | −8.2% | $207M | −29.7% | $587.9M | 3.6% | 24.6% | 2.5% |
| 2025Q1 | 2025-03-31 | $876.2M | +65.9% | $243.1M | −5.3% | $633.1M | 4.4% | 22.8% | 2.6% |
| 2024Q4 | 2024-12-31 | $542.3M | −39.5% | $252.4M | −0.2% | $289.9M | 4.6% | 51.3% | 2.7% |
口径:TTM = 近四个离散单季之和;FCF = OCF − CapEx;CapEx 密度 = CapEx/营收 TTM;FCF≤0 时 SBC/FCF 不计算。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| −39.4 |
| 2026Q1 | 2026-03-31 | $1.12B | +0.5% | +16.7% | −16.2pp | 281.6 | −55.4 |
| 2025Q4 | 2025-12-31 | $1.13B | +3.6% | +13.3% | −9.6pp | 299.6 | −39.8 |
| 2025Q3 | 2025-09-30 | $1.14B | +3.3% | +14.7% | −11.3pp | 301.6 | −81.7 |
| 2025Q2 | 2025-06-30 | $1.14B | +11.4% | +11.9% | −0.5pp | 302.5 | −36.9 |
| 2025Q1 | 2025-03-31 | $1.11B | −7.7% | +6.2% | −14.0pp | 337.0 | −47.0 |
| 2024Q4 | 2024-12-31 | $1.09B | +20.3% | +9.4% | +10.8pp | 339.4 | +10.9 |
口径:剪刀差 = 存货同比 − 营收同比(pp,正值=存货增速快于营收);DIO = 存货/销货成本 × 91.25 天。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 2026-11-09 | 2026-11-09 | Zovighian Bernard J | CEO | S | 13,916 | $102.78 | $1.43M | ✓ |
| 2026-11-09 | 2026-11-09 | Zovighian Bernard J | CEO | S | 9,184 | $103.39 | $949.49K | ✓ |
| 2026-11-09 | 2026-11-09 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S | 48,900 | $103.05 | $5.04M | ✓ |
| 2026-10-08 | 2026-10-08 | Lippis Daniel J. | CVP, TAVR | S | 619 | $85.65 | $53.02K | ✓ |
| 2026-09-11 | 2026-09-11 | Lippis Daniel J. | CVP, TAVR | S | 619 | $87.51 | $54.17K | ✓ |
| 2026-08-31 | 2026-08-31 | Dahl Andrew M. | SVP, Corporate Controller | S | 544 | $91.06 | $49.54K |
| 2026-08-28 | 2026-08-28 | Bruls Annette | CVP, EMEACLA | S | 2,644 | $89.98 | $237.91K |
| 2026-08-26 | 2026-08-26 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | S | 1,154 | $91.76 | $105.89K |
| 2026-08-26 | 2026-08-26 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | S | 30,646 | $90.99 | $2.79M |
| 2026-08-26 | 2026-08-26 | Markowitz Wayne | CVP, JAPAC | S | 1,240 | $91.47 | $113.42K |
| 2026-08-11 | 2026-08-11 | Lippis Daniel J. | CVP, TAVR | S | 619 | $92.03 | $56.97K | ✓ |
| 2026-07-30 | 2026-07-30 | Markowitz Wayne | CVP, JAPAC | S | 146.31 | $86.03 | $12.59K |
| 2026-07-28 | 2026-07-28 | Markowitz Wayne | CVP, JAPAC | S | 9,628 | $85.06 | $818.96K |
| 2026-07-27 | 2026-07-27 | Zovighian Bernard J | CEO | S | 2,920.55 | $83.93 | $245.12K |
| 2026-07-10 | 2026-07-10 | Lippis Daniel J. | CVP, TAVR | S | 619 | $91.70 | $56.76K | ✓ |
| 2026-06-30 | 2026-06-30 | Lippis Daniel J. | CVP, TAVR | S | 619 | $91.40 | $56.58K | ✓ |
| 2026-06-17 | 2026-06-17 | Zovighian Bernard J | CEO | S | 523 | $87.92 | $45.98K | ✓ |
| 2026-05-29 | 2026-05-29 | Dahl Andrew M. | SVP, Corporate Controller | S | 567.53 | $86.08 | $48.85K |
| 2026-05-27 | 2026-05-27 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S | 23,145 | $86.42 | $2M |
| 2026-05-22 | 2026-05-22 | Chopra Daveen | CVP, TMTT & Surgical | S | 1,500 | $84.60 | $126.9K |
| 2026-05-18 | 2026-05-18 | Lippis Daniel J. | CVP, TAVR | S | 620 | $81.14 | $50.31K | ✓ |
| 2026-05-15 | 2026-05-18 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S | 9,968 | $82.07 | $818.07K |
| 2026-05-15 | 2026-05-18 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S | 8,000 | $81.82 | $654.56K |
| 2026-05-12 | 2026-05-12 | Zovighian Bernard J | CEO | S | 845 | $78.40 | $66.25K | ✓ |
| 2026-05-12 | 2026-05-12 | Zovighian Bernard J | CEO | S | 35,506 | $77.92 | $2.77M | ✓ |
| 2026-05-11 | 2026-05-11 | Markowitz Wayne | CVP, JAPAC | S | 593 | $79.73 | $47.28K |
| 2026-05-04 | 2026-05-04 | Lippis Daniel J. | CVP, TAVR | S | 1,019 | $83.98 | $85.58K | ✓ |
| 2026-05-01 | 2026-05-04 | Lippis Daniel J. | CVP, TAVR | S | 1,000 | $82.99 | $82.99K | ✓ |
| 2026-05-01 | 2026-05-04 | Lippis Daniel J. | CVP, TAVR | S | 19 | $83.99 | $1.6K | ✓ |
| 2026-04-09 | 2026-04-09 | Ullem Scott B. | CVP, Chief Financial Officer | S | 4,676 | $80.50 | $376.42K | ✓ |
| 2026-04-09 | 2026-04-09 | Ullem Scott B. | CVP, Chief Financial Officer | S | 8,324 | $79.79 | $664.17K | ✓ |
| 2026-04-06 | 2026-04-06 | Lippis Daniel J. | CVP, TAVR | S | 1,019 | $80.98 | $82.52K | ✓ |
| 2026-04-02 | 2026-04-02 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S | 18,004 | $80.05 | $1.44M | ✓ |
| 2026-04-02 | 2026-04-02 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S | 4,676 | $80.59 | $376.84K | ✓ |
| 2026-03-11 | 2026-03-11 | Ullem Scott B. | CVP, Chief Financial Officer | S | 5,099 | $84.46 | $430.66K | ✓ |
| 2026-03-11 | 2026-03-11 | Ullem Scott B. | CVP, Chief Financial Officer | S | 7,901 | $85.21 | $673.24K | ✓ |
| 2026-03-11 | 2026-03-11 | Lippis Daniel J. | CVP, TAVR | S | 1,019 | $85.38 | $87K | ✓ |
| 2026-03-02 | 2026-03-02 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S | 11,340 | $85.93 | $974.45K | ✓ |
| 2026-02-25 | 2026-02-26 | BOBO DONALD E JR | CVP,Strategy/Corp Development | S | 24,000 | $83.84 | $2.01M |
口径:Form 4/4A 公开市场买入(P)与卖出(S),申报人为董事或高管;汇总与集群为近 365 天,明细为最近 40 笔。 · 数据截至 2026-11-16 · 来源:SEC EDGAR Form 4
口径:SI 来自 FINRA(双周结算);SI% 分母 = SEC 封面总股本;借券费为 IBKR 报价(非全市场);卖空占比 = 当日卖空量/总成交量。 · 数据截至 SI 2026-10-30 · Reg SHO 2026-11-16 · 借券 2026-11-11 · 沿用上一版 · 来源:FINRA、IBKR、iBorrowDesk